May 12,2017

Senseonics, TypeZero partner on artificial pancreas research

Senseonics, a Germantown, Maryland company working on a pill-sized, implantable continuous glucose monitor that can last 90 days without needing replacement, will work with digital, personalized medicine company TypeZero Technologies on a project to integrate readings from Senseonics devices into TypeZero’s inControl software platform, which can either be used for decision support for manual insulin dosing or automatically adjust and regulate insulin delivery via an insulin pump. The two have signed an R&D licensing agreement.

COLLABORATION PARTNERSHIP

#r&d

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
May 15,2017

Cedars-Sinai signs 3-year deal with Noteworth for on-demand patient-generated health data

Cedars-Sinai Hospital in Los Angeles has partnered with Noteworth, a startup from the second cohort of its accelerator, to give physicians in several hospital departments new tools to monitor the health of their patients at home. The deal is a three-year engagement. Noteworth offers a novel platform for on-demand patient-generated health data. With the system, a physician can order PGHD for a patient from inside the electronic health record, and can select from a menu of vital signs such as blood pressure, blood glucose level and weight, as well as behavioral metrics like medication adherence, mood and activity.

COLLABORATION PARTNERSHIP

#r&d

#rpm

View Analyst & Ambassador Comments
Go to original news
May 01,2017

Incidence of severe hypoglycemia in children with type 1 diabetes in the Nordic countries in the period 2008–2012: association with hemoglobin A1c and treatment modality

Treatment of type 1 diabetes has been intensified aiming at normalizing blood glucose, which may increase the risk of severe hypoglycemia (SH). Research aimed to compare the incidence of SH events in the four Nordic countries Denmark, Iceland, Norway and Sweden, and to assess the influence of hemoglobin A1c (HbA1c) and treatment modalities on the frequency of SH; particularly, to explore if a HbA1c target ≤6.7% (50 mmol/mol) is feasible. As a result, the study found out that risk of SH differs between the Nordic countries with the lowest risk in Sweden. Pump therapy was associated with decreased risk of SH.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
May 02,2017

One Drop Chrome Blood Glucose Monitoring System Now Available on Amazon Prime

One Drop today announced that its blood glucose monitoring system One Drop | Chrome is now available for purchase on Amazon Prime. One Drop is a diabetes management platform that harnesses the power of mobile computing and data science to empower people with diabetes to improve their health and lives. Through Amazon Prime, One Drop can now be ordered and delivered directly to the user’s doorstep in two days or less, creating an on-demand healthcare experience for a chronic condition that requires constant management.

PRODUCT

#bgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 02,2017

BD Announces Results for 2017 Second Fiscal Quarter

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.969 billion for the second fiscal quarter ended March 31, 2017. This represents a decrease of 3.2 percent from the prior-year period due to the divestiture of the Respiratory Solutions business that was completed in October 2016. The Company's Diabetes Care revenue reached to $125 million in the second quarter, with a 1% decrease YoY.

View Analyst & Ambassador Comments
Go to original news
May 04,2017

MannKind and One Drop to collaborate on delivering better health outcomes for people with diabetes

MannKind Corporation (MNKD) TASE:MNKD) and One Drop today announced that they have signed a memorandum of understanding to enter into a collaborative agreement that would extend One Drop’s subscription service and digital health platform by adding Afrezza as a rapid-acting insulin offering. The partnership also includes Design Innovation around packaging and exploration of a reusable Afrezza Inhaler with integrated Bluetooth technology.

COLLABORATION PARTNERSHIP

#product & service

#mobile app

#bgm

View Analyst & Ambassador Comments
Go to original news
May 07,2017

BD Announces Offerings of $2.25 Billion of Common Stock and $2.25 Billion of Depositary Shares Representing Interests in Mandatory Convertible Preferred Stock

BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has commenced registered offerings of $2.25 billion of common stock, par value $1.00 per share, and $2.25 billion of depositary shares, each representing a 1/20th interest in its mandatory convertible preferred stock, par value $1.00 per share, Series A.

View Analyst & Ambassador Comments
Go to original news
May 08,2017

Insulet Reports First Quarter 2017 Financial Results

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced financial results for the three months ended March 31, 2017. The Company's first quarter 2017 revenue increased 25% to $101.7 million, compared to revenue of $81.2 million in the first quarter of 2016.

View Analyst & Ambassador Comments
Go to original news
May 09,2017

"Most Innovative Brand of the Year" by the Plus X Award Goes to Beurer

For the seventh time in a row, Beurer was named "Most Innovative Brand of the Year" by the Plus X Award in 2017. This highest award in the competition is given to those participants who have previously won the most Plus X quality seals in their product group was also awarded "Best Design Brand" for the fourth time in a row this year.

View Analyst & Ambassador Comments
Go to original news
May 15,2017

BD to Present at Investor Healthcare Conferences

BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following upcoming investor healthcare conferences: Bank of America Merrill Lynch 2017 Healthcare Conference on May 17, 2017 at 11:40 a.m. EDT, Jefferies 2017 Global Healthcare Conference on June 8, 2017 at 9:00 a.m. EDT, and Goldman Sachs 38th Annual Global Healthcare Conference on June 13, 2017 at 11:40 a.m. EDT.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES